William J Tester
Overview
Explore the profile of William J Tester including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
484
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iskandar A, Zarrabi K, Tester W
Can J Urol
. 2024 Sep;
31(4):11921-11930.
PMID: 39217515
Introduction: Renal cell carcinoma is as the most prevalent form of kidney cancer, with the clear cell subtype comprising approximately 75% of cases. The identification of predictive and prognostic biomarkers...
2.
Palecki J, Bhasin A, Bernstein A, Mille P, Tester W, Kelly W, et al.
Cancer Biol Ther
. 2024 May;
25(1):2356820.
PMID: 38801069
Novel T-cell immunotherapies such as bispecific T-cell engagers (BiTEs) are emerging as promising therapeutic strategies for prostate cancer. BiTEs are engineered bispecific antibodies containing two distinct binding domains that allow...
3.
Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma
Eturi A, Bhasin A, Zarrabi K, Tester W
Molecules
. 2024 Apr;
29(8).
PMID: 38675715
Urothelial carcinoma (UC) is the fourth most prevalent cancer amongst males worldwide. While patients with non-muscle-invasive disease have a favorable prognosis, 25% of UC patients present with locally advanced disease...
4.
Zhang Z, Luo R, Kelly W, Chen J, Donahue S, Ip K, et al.
Prostate Cancer Prostatic Dis
. 2023 Dec;
27(2):339-347.
PMID: 38057610
Background: Identification of emerging molecular biomarkers on circulating tumor cells (CTCs) represents an attractive feature of liquid biopsy that facilitates precision and tailored medicine in the management of metastatic castration-resistant...
5.
Mark J, Gomella L, Lallas C, Smentkowski K, Calvaresi A, Handley N, et al.
Can J Urol
. 2023 Jun;
30(3):11526-11531.
PMID: 37344462
Introduction: To report the impact of our 25-year multidisciplinary care delivery model experience on patients with muscle invasive bladder cancer treated at our National Cancer Institute (NCI)-designated Sidney Kimmel Cancer...
6.
Magliocco A, Moughan J, Miyamoto D, Simko J, Shipley W, Gray P, et al.
JAMA Netw Open
. 2022 Nov;
5(11):e2242378.
PMID: 36383379
Importance: Bladder-preserving trimodality therapy can be an effective alternative to radical cystectomy for treatment of muscle-invasive bladder cancer (MIBC), but biomarkers are needed to guide optimal patient selection. The DNA...
7.
Steuer C, Jegede O, Dahlberg S, Wakelee H, Keller S, Tester W, et al.
J Thorac Oncol
. 2021 Feb;
16(6):960-967.
PMID: 33539971
Introduction: Smoking cessation has been reported to benefit patients even after a diagnosis of lung cancer. We studied the smoking behavior of patients who participated in a phase 3 trial...
8.
Wakelee H, Dahlberg S, Keller S, Tester W, Gandara D, Graziano S, et al.
Lancet Oncol
. 2017 Nov;
18(12):1610-1623.
PMID: 29129443
Background: Adjuvant chemotherapy for resected early-stage non-small-cell lung cancer (NSCLC) provides a modest survival benefit. Bevacizumab, a monoclonal antibody directed against VEGF, improves outcomes when added to platinum-based chemotherapy in...
9.
Belani C, Dahlberg S, Rudin C, Fleisher M, Chen H, Takebe N, et al.
Cancer
. 2016 May;
122(15):2371-8.
PMID: 27163943
Background: Preclinical targeting of the hedgehog pathway by vismodegib and of insulin-like growth factor 1 receptor by cixutumumab enhances the efficacy of chemotherapy and also demonstrates activity against the tumor...
10.
Mak R, Hunt D, Shipley W, Efstathiou J, Tester W, Hagan M, et al.
J Clin Oncol
. 2014 Nov;
32(34):3801-9.
PMID: 25366678
Purpose: Multiple prospective Radiation Therapy Oncology Group (RTOG) protocols have evaluated bladder-preserving combined-modality therapy (CMT) for muscle-invasive bladder cancer (MIBC), reserving cystectomy for salvage treatment. We performed a pooled analysis...